Title:Preclinical Studies and Clinical Trials with Mesenchymal Stem Cell for Demyelinating Diseases: A Systematic Review
Volume: 16
Issue: 8
Author(s): Zahra Esmaeilizade, Bahar Mohammadi, Mir Davood Omrani, Sayyed Mohammad Hossein Ghaderian, Masoumeh Rajabibazl and Zahra Fazeli*
Affiliation:
- Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran,Iran
Keywords:
Mesenchymal stem cells, multiple sclerosis, cellular therapy, remyelination, stabilization, transplantation.
Abstract:
Aim: Different studies have been performed to investigate stem cell administration as a
promising tool for recovery of injured tissue in multiple sclerosis (MS), the most common demyelinating
disease.
Methods: In the present systematic review, the electronic databases of PubMed and ScienceDirect
were searched to screen English language studies published until April 2020.
Results: The results obtained from experimental autoimmune encephalomyelitis (EAE) animals revealed
that modified mesenchymal stem cells (MSCs) transplantation was associated with remyelination,
inflammation suppression and oligodendrocyte precursor cells regeneration. Clinical trials
indicated that 70% of the patients with MS showed disease stabilization following MSCs administration.
Conclusion: Although MSC therapy has showed to be effective in the improvement of some patients
with MS, designing larger placebo-controlled clinical trials with MSCs expressing immune-
regulators or MSCs-exosomes may provide a novel viewpoint in the treatment of MS.
